1α,25(OH)2-3-epi-vitamin D3, a Natural Physiological Metabolite of Vitamin D3: Its Synthesis, Biological Activity and Crystal Structure with Its Receptor

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Apr 13

PMID 21483824

Citations 27

Authors

Ferdinand Molnar

Rita Sigueiro

Yoshiteru Sato

Clarisse Araujo

Inge Schuster

Pierre Antony

Jean Peluso

Christian Muller

Antonio Mourino

Dino Moras

Natacha Rochel

Affiliations

Soon will be listed here.

Abstract

Background: The 1α,25-dihydroxy-3-epi-vitamin-D3 (1α,25(OH)2-3-epi-D3), a natural metabolite of the seco-steroid vitamin D3, exerts its biological activity through binding to its cognate vitamin D nuclear receptor (VDR), a ligand dependent transcription regulator. In vivo action of 1α,25(OH)2-3-epi-D3 is tissue-specific and exhibits lowest calcemic effect compared to that induced by 1α,25(OH)2D3. To further unveil the structural mechanism and structure-activity relationships of 1α,25(OH)2-3-epi-D3 and its receptor complex, we characterized some of its in vitro biological properties and solved its crystal structure complexed with human VDR ligand-binding domain (LBD).

Methodology/principal Findings: In the present study, we report the more effective synthesis with fewer steps that provides higher yield of the 3-epimer of the 1α,25(OH)2D3. We solved the crystal structure of its complex with the human VDR-LBD and found that this natural metabolite displays specific adaptation of the ligand-binding pocket, as the 3-epimer maintains the number of hydrogen bonds by an alternative water-mediated interaction to compensate the abolished interaction with Ser278. In addition, the biological activity of the 1α,25(OH)2-3-epi-D3 in primary human keratinocytes and biochemical properties are comparable to 1α,25(OH)2D3.

Conclusions/significance: The physiological role of this pathway as the specific biological action of the 3-epimer remains unclear. However, its high metabolic stability together with its significant biologic activity makes this natural metabolite an interesting ligand for clinical applications. Our new findings contribute to a better understanding at molecular level how natural metabolites of 1α,25(OH)2D3 lead to significant activity in biological systems and we conclude that the C3-epimerization pathway produces an active metabolite with similar biochemical and biological properties to those of the 1α,25(OH)2D3.

Citing Articles

Vitamin D: A key player in COVID-19 immunity and lessons from the pandemic to combat immune-evasive variants.

Sabit H, Abdel-Ghany S, Abdallah M, Abul-Maaty O, Khoder A, Shoman N Inflammopharmacology. 2024; 32(6):3631-3652.

PMID: 39406981 PMC: 11550250. DOI: 10.1007/s10787-024-01578-w.

4-Hydroxy-1α,25-Dihydroxyvitamin D: Synthesis and Structure-Function Study.

Peluso-Iltis C, Pierrat N, Rovito D, Osz J, Sawada D, Kittaka A Biomolecules. 2024; 14(5).

PMID: 38785958 PMC: 11117473. DOI: 10.3390/biom14050551.

Dietary 25 Hydroxyvitamin D3 Improved Serum Concentration Level and Alkaline Phosphatase Activity during Lactation but Had Meager Impact on Post-Farrowing Reproductive Performance in Sows.

Okafor P, Homwong N Animals (Basel). 2024; 14(3).

PMID: 38338062 PMC: 10854743. DOI: 10.3390/ani14030419.

Vitamin D and Its Metabolites Status before and during Chemotherapy in Caucasian Breast Cancer Patients.

Kimsa-Furdzik M, Bednarek A, Hibner G, Czajka-Francuz P, Cison-Jurek S, Karawasiecka D Metabolites. 2023; 13(9).

PMID: 37755276 PMC: 10534610. DOI: 10.3390/metabo13090996.

A Mathematical Model for Determining the Body's Fluctuating Need for and Synthesis of Active Vitamin D.

Maloney S Biomedicines. 2023; 11(2).

PMID: 36830861 PMC: 9953299. DOI: 10.3390/biomedicines11020324.

References

Sekimoto H, Weiskopf A, Vouros P, Muralidharan K, Okamura W, Uskokovic M . 1alpha,25-dihydroxy-3-epi-vitamin D3: in vivo metabolite of 1alpha,25-dihydroxyvitamin D3 in rats. FEBS Lett. 1999; 448(2-3):278-82. DOI: 10.1016/s0014-5793(99)00377-4. View

Reddy M, Stoynova L, Acevedo A, Collins E . Residues of the human nuclear vitamin D receptor that form hydrogen bonding interactions with the three hydroxyl groups of 1alpha,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol. 2007; 103(3-5):347-51. DOI: 10.1016/j.jsbmb.2006.12.045. View

Murshudov G, Vagin A, Dodson E . Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr. 1997; 53(Pt 3):240-55. DOI: 10.1107/S0907444996012255. View

Garabedian M, Lieberherr M, Nguyen T, Corvol M, Du Bois M, BALSAN S . The in vitro production and activity of 24, 25-dihydroxycholecalciferol in cartilage and calvarium. Clin Orthop Relat Res. 1978; (135):241-8. View

Carlberg C, Bendik I, Wyss A, Meier E, Sturzenbecker L, Grippo J . Two nuclear signalling pathways for vitamin D. Nature. 1993; 361(6413):657-60. DOI: 10.1038/361657a0. View

DeLuca H, Suda T, Schnoes H, Tanaka Y, Holick M . 25,26-dihydroxycholecalciferol, a metabolite of vitamin D3 with intestinal calcium transport activity. Biochemistry. 1970; 9(24):4776-80. DOI: 10.1021/bi00826a022. View

Campbell M, Adorini L . The vitamin D receptor as a therapeutic target. Expert Opin Ther Targets. 2006; 10(5):735-48. DOI: 10.1517/14728222.10.5.735. View

Vaisanen S, Dunlop T, Sinkkonen L, Frank C, Carlberg C . Spatio-temporal activation of chromatin on the human CYP24 gene promoter in the presence of 1alpha,25-Dihydroxyvitamin D3. J Mol Biol. 2005; 350(1):65-77. DOI: 10.1016/j.jmb.2005.04.057. View

Bischof M, Weiskopf A, Vouros P, Cross H, Peterlik M, Reddy G . Differentiation-related pathways of 1 alpha,25-dihydroxycholecalciferol metabolism in human colon adenocarcinoma-derived Caco-2 cells: production of 1 alpha,25-dihydroxy-3epi-cholecalciferol. Exp Cell Res. 1998; 241(1):194-201. DOI: 10.1006/excr.1998.4044. View

10.

Gomez-Reino C, Vitale C, Maestro M, Mourino A . Pd-catalyzed carbocyclization-Negishi cross-coupling cascade: a novel approach to 1alpha,25-dihydroxyvitamin D3 and analogues. Org Lett. 2005; 7(26):5885-7. DOI: 10.1021/ol052489c. View

11.

Bouillon R, Eelen G, Verlinden L, Mathieu C, Carmeliet G, Verstuyf A . Vitamin D and cancer. J Steroid Biochem Mol Biol. 2006; 102(1-5):156-62. DOI: 10.1016/j.jsbmb.2006.09.014. View

12.

Wichmann J, DeLuca H, Schnoes H, Horst R, SHEPARD R, Jorgensen N . 25-Hydroxyvitamin D3 26,23-lactone: a new in vivo metabolite of vitamin D. Biochemistry. 1979; 18(22):4775-80. DOI: 10.1021/bi00589a002. View

13.

Takeyama K, Masuhiro Y, Fuse H, Endoh H, Murayama A, Kitanaka S . Selective interaction of vitamin D receptor with transcriptional coactivators by a vitamin D analog. Mol Cell Biol. 1999; 19(2):1049-55. PMC: 116035. DOI: 10.1128/MCB.19.2.1049. View

14.

Daniewski A, Garofalo L, Hutchings S, Kabat M, Liu W, Okabe M . Efficient synthesis of the A-ring phosphine oxide building block useful for 1 alpha,25-dihydroxy vitamin D(3) and analogues. J Org Chem. 2002; 67(5):1580-7. DOI: 10.1021/jo0161577. View

15.

BLIGH E, Dyer W . A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959; 37(8):911-7. DOI: 10.1139/o59-099. View

16.

Rochel N, Wurtz J, Mitschler A, Klaholz B, Moras D . The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell. 2000; 5(1):173-9. DOI: 10.1016/s1097-2765(00)80413-x. View

17.

Horst R . 25-OHD3-26,23-lactone: a metabolite of vitamin D3 that is 5 times more potent than 25-OHD3 in the rat plasma competitive protein binding radioassay. Biochem Biophys Res Commun. 1979; 89(1):286-93. DOI: 10.1016/0006-291x(79)90976-8. View

18.

Ishizuka S, Norman A . Metabolic pathways from 1 alpha,25-dihydroxyvitamin D3 to 1 alpha,25-dihydroxyvitamin D3-26,23-lactone. Stereo-retained and stereo-selective lactonization. J Biol Chem. 1987; 262(15):7165-70. View

19.

Kamao M, Tatematsu S, Hatakeyama S, Sakaki T, Sawada N, Inouye K . C-3 epimerization of vitamin D3 metabolites and further metabolism of C-3 epimers: 25-hydroxyvitamin D3 is metabolized to 3-epi-25-hydroxyvitamin D3 and subsequently metabolized through C-1alpha or C-24 hydroxylation. J Biol Chem. 2004; 279(16):15897-907. DOI: 10.1074/jbc.M311473200. View

20.

Rochel N, Egea P, Juntunen K, Garnier J, Vihko P, Moras D . Functional and structural characterization of the insertion region in the ligand binding domain of the vitamin D nuclear receptor. Eur J Biochem. 2001; 268(4):971-9. DOI: 10.1046/j.1432-1327.2001.01953.x. View